Computational Modeling of ERBB2-Amplified Breast Cancer Identifies Combined ErbB2/3 Blockade as Superior to the Combination of MEK and AKT Inhibitors

Sci. Signal.  13 Aug 2013:
Vol. 6, Issue 288, pp. ra68
DOI: 10.1126/scisignal.2004008

This article has a correction. Please see:

Log in to view full text

Via your Institution

Log in through your institution

Log in through your institution

Related Content

Navigate This Article